Changes in reporting adverse drug reactions to Eudravigilance

MAHs need to submit electronically to EVPM information on all non-serious suspected adverse reactions that occur in the Union, within 90 days following the day on which the MAH concerned gained knowledge of the event.

There is no need to additionally notify the State Agency of Medicine.

There will be no changes to the reporting of SUSARs during clinical trials.